Evidence map›Paper›PMID 40550563›Full record

ArticleJournal for immunotherapy of cancer2025

Novel fusion superkine,

Amit Kumar, Praveen Bhoopathi, Padmanabhan Mannangatti, Santanu Maji, Anjan K Pradhan, Esha Madan, Alexander L Klibanov, Rajan Gogna, David D Limbrick, Luni Emdad and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Amit KumarVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Praveen BhoopathiVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Padmanabhan MannangattiVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Santanu MajiVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Anjan K PradhanVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Esha MadanVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Alexander L KlibanovDivision of Cardiovascular Medicine, Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
Rajan GognaVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
David D LimbrickDepartment of Neurosurgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Luni EmdadVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Swadesh K DasVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA paul.fisher@vcuhealth.org swadesh.das@vcuhealth.org.
Paul B FisherVCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA paul.fisher@vcuhealth.org swadesh.das@vcuhealth.org.ORCID http://orcid.org/0000-0002-0085-4546

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
Mouse Model and Pathological Analysis CoreP01CA275740 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Devanand Sarkar · 2024 to 2026
$10.6M
Interplay between tumor and microenvironment in bone metastasisR01CA259599 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B, WANG, XIANG-YANG SHAWN · 2021 to 2025
$2.3M
NCI NIH HHS P01 CA275740NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA259599
6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) is a rapidly growing, aggressive brain tumor with very poor prognosis without currently effective therapies. The immunosuppressive nature of the tumor microenvironment (TME) in GBM hinders the development of effective tumor-eradicating immunotherapies. This hostile TME can be modulated by administering immune-activating cytokines in combination with agents inducing tumor cell death. To achieve these objectives, we sought to harness the cancer-selective cell death-inducing properties of an enhanced "Superkine" version of melanoma differentiation associated gene-7/interleukin-24,

methodsA fusion "Superkine" (

resultsThe

conclusionIn summary, treatment with an

Indexed as

Brain NeoplasmsGlioblastomaImmunotherapyInterleukin-15InterleukinsRecombinant Fusion ProteinsAnimalsCell Line, TumorHumansInterleukin-24MiceTumor MicroenvironmentInterleukin-15Interleukin-24InterleukinsRecombinant Fusion ProteinsCytokineGene therapyImmune modulatoryImmunotherapyNatural killer - NK

Identifiers

PMID40550563
PMCPMC12184379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.